Pharmacologist and translational drug-development leader PhD, PharmD with more than a decade of experience moving assets from discovery to IND and FIH across oncology, radiopharmaceuticals, immuno-oncology, genetic engineering, and precision medicine.
Lead cross-functional pharmacology and biomarker strategy, direct GLP and GCLP studies, and author CTD modules for FDA, EMA, and Health Canada.
Led more than 25 preclinical programs; integrated PK PD, biodistribution, and histology to drive dose selection and target engagement.
Regulatory-facing scientist with successful FDA Type B, EMA advice, and Health Canada CTA inputs; delivered IND and CTA-ready packages.
Team builder and mentor; established governance, SOPs, and training to raise execution quality.
Funding and BD experience; secured 1M in internal and non-dilutive grants, co-crafted proposals and scientific narratives, and frequently presented to KOLs and boards.
Track record includes more than 10 publications, including Cancer Cell and Cell Chem Biol, US patent co-inventor status, Chairman Rising Star 2025, and Budding Innovator 2024.
Focus areas include translational and clinical pharmacology, biomarker strategy, radiopharma, IND enablement, CRO governance, and cross-functional leadership.